{"title":"Calaspargase Pegol（Asparlas）","authors":"Cadth","doi":"10.51731/cjht.2024.820","DOIUrl":null,"url":null,"abstract":"\nCADTH recommends that Asparlas be reimbursed by public drug plans as a component of a multiagent chemotherapeutic (MAC) regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 to 21 years if certain conditions are met. \nAsparlas should only be covered to treat children and young adults with ALL. \nAsparlas should only be reimbursed as part of a MAC regimen. Asparlas should be prescribed by clinicians with expertise in the management of ALL, and the cost of Asparlas should not exceed the drug program cost of treatment with pegaspargase. \n","PeriodicalId":9437,"journal":{"name":"Canadian Journal of Health Technologies","volume":"7 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Calaspargase Pegol (Asparlas)\",\"authors\":\"Cadth\",\"doi\":\"10.51731/cjht.2024.820\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\nCADTH recommends that Asparlas be reimbursed by public drug plans as a component of a multiagent chemotherapeutic (MAC) regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 to 21 years if certain conditions are met. \\nAsparlas should only be covered to treat children and young adults with ALL. \\nAsparlas should only be reimbursed as part of a MAC regimen. Asparlas should be prescribed by clinicians with expertise in the management of ALL, and the cost of Asparlas should not exceed the drug program cost of treatment with pegaspargase. \\n\",\"PeriodicalId\":9437,\"journal\":{\"name\":\"Canadian Journal of Health Technologies\",\"volume\":\"7 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.51731/cjht.2024.820\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51731/cjht.2024.820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
CADTH 建议，在满足特定条件的情况下，Asparlas 可作为治疗 1 至 21 岁儿童和年轻成人急性淋巴细胞白血病 (ALL) 的多药化疗 (MAC) 方案的组成部分，获得公共药品计划的报销。Asparlas 只能用于治疗儿童和年轻成人 ALL 患者。Asparlas 只能作为 MAC 方案的一部分获得报销。Asparlas应由具有ALL治疗专业知识的临床医生处方，且Asparlas的费用不应超过使用pegaspargase治疗的药物计划费用。
CADTH recommends that Asparlas be reimbursed by public drug plans as a component of a multiagent chemotherapeutic (MAC) regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 to 21 years if certain conditions are met.
Asparlas should only be covered to treat children and young adults with ALL.
Asparlas should only be reimbursed as part of a MAC regimen. Asparlas should be prescribed by clinicians with expertise in the management of ALL, and the cost of Asparlas should not exceed the drug program cost of treatment with pegaspargase.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
